Clinical Trials Logo

Relapsed Ewing Sarcoma clinical trials

View clinical trials related to Relapsed Ewing Sarcoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04661852 Completed - Clinical trials for Refractory Osteosarcoma

Cabozantinib With Topotecan-Cyclophosphamide

Start date: December 23, 2020
Phase: Phase 1
Study type: Interventional

This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. - The names of the drugs are: - Cabozantinib - Topotecan - Cyclophosphamide - The names of the non-investigational supportive care drugs are: - Filgrastim, pegfilgrastim, or a related growth factor.

NCT ID: NCT02546544 Completed - Clinical trials for Refractory Ewing Sarcoma

Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma

LINES
Start date: March 2014
Phase: Phase 2
Study type: Interventional

This is an international, multi-centre, single arm Bayesian designed phase 2 study to identify and determine the safety and activity of anti-IGF-1/IR inhibition in patients with relapsed and/or refractory ESFT. Approximately 40 patients will be recruited from 5-7 European centres. Each patient will be treated with single agent linsitinib, 600 mg orally once a day for days 1-3, 8-10 and 15-17 on a 21 day cycle until disease progression or undue toxicity.